Cancer Immunotherapy Market To Surpass USD 24 Billion by 2020
There are several advantages which are offered by immunother...
expression of the tumor cells. Thus, it becomes challenging for the individual cells to overcome a potent
immune response....
Upcoming SlideShare
Loading in...5
×

Cancer immunotherapy market to surpass usd 24 billion by 2020

40

Published on

“Cancer Immunotherapy Market & Clinical Pipeline Insight” Report Highlights:

Cancer Immunotherapy Market Overview
Cancer Immunotherapy Market Dynamics
Cancer Immunotherapy Pipeline: 1080 Drug in Clinical Pipeline
Cancer Monoclonal Antibodies Clinical Pipeline by Phase & Country
Cancer Vaccine Clinical Pipeline by Phase & Country
Oncolytic Viruses Clinical Pipeline by Phase & Country
Cancer Cytokine Therapy Clinical Trial Insight by Phase & Country
Cancer Cell Therapy Clinical Trial Insight by Phase & Country
Currently there are 605 Cancer Monoclonal Antibodies, 289 Cancer Vaccines, 40 Oncolytic Viruses Drugs, 64 Cytokines Therapies & 82 Cell Therapies are in Clinical Pipeline

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
40
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "Cancer immunotherapy market to surpass usd 24 billion by 2020"

  1. 1. Cancer Immunotherapy Market To Surpass USD 24 Billion by 2020 There are several advantages which are offered by immunotherapy in the treatment of some types of cancers as compared to traditional chemotherapies and molecularly targeted agents. Cancer immunotherapy, in recent years has become one of the most sought after treatment options for cancer. The major reason for this rising popularity is the dependence of this method on biological molecules which occur naturally and are used to enhance the immune system. This factor has made cancer immunotherapy the most natural and patient friendly when compared to all the scientifically validated methods for treating cancer. In some cases, immunotherapy is alone used to treat cancer, while in some other cases it is used in combination with traditional treatments in order to enhance their effects. A major benefit of using this method and also for the rising popularity is that immunotherapy promises to be less toxic in nature than radiation, chemotherapy, and surgery. Additionally, in most cases, immunotherapy is capable of offering a different mode of attack on the tumor. This allows both the patients and doctors to be more confident of the results of the treatment with minimal side effects. “Cancer Immunotherapy Market & Clinical Pipeline Insight” Report Highlights:  Cancer Immunotherapy Market Overview  Cancer Immunotherapy Market Dynamics  Cancer Immunotherapy Pipeline: 1080 Drug in Clinical Pipeline  Cancer Monoclonal Antibodies Clinical Pipeline by Phase & Country  Cancer Vaccine Clinical Pipeline by Phase & Country  Oncolytic Viruses Clinical Pipeline by Phase & Country  Cancer Cytokine Therapy Clinical Trial Insight by Phase & Country  Cancer Cell Therapy Clinical Trial Insight by Phase & Country  Currently there are 605 Cancer Monoclonal Antibodies, 289 Cancer Vaccines, 40 Oncolytic Viruses Drugs, 64 Cytokines Therapies & 82 Cell Therapies are in Clinical Pipeline There are several advantages which are offered by immunotherapy in the treatment of some types of cancers as compared to traditional chemotherapies and molecularly targeted agents. Generally, the targeted therapies tend to depend mostly on the oncogenic dependency of the cell on specific pathways. However, it is possible that in some cases, these cells could activate compensatory signaling to make them resistant to these therapies. Thus, studies are being conducted to combine multiple receptor tyrosine kinase inhibitors to prevent this emergence of resistance. However, with the use of such combinations, there is a high risk of rising toxicities also, which could possibly limit their feasibility. On the contrary, immunotherapy has the capability to target and eradicate micrometastatic disease which is dependent mainly on the protein
  2. 2. expression of the tumor cells. Thus, it becomes challenging for the individual cells to overcome a potent immune response. Additionally, the extra toxicity which is associated with combinations of multiple tyrosine kinase inhibitors is eradicated completely. Also, additional epitopes could be easily included in cancer vaccines so as to reduce the chance of immune evasion. For Report Contact: avinash@kuickresearch.com

×